Regen BioPharma Inc. (OTCMKTS:RGBPP) may seem dead silent in the market ever since it announced it had made a submission to the Food and Drugs Administration on the use of a new novel method that can activate the immune system to kill cancer. However, RGBPP is showing great positive signs under the surface and it could be just a matter of some time before Wall Street takes notice. While the stock is trading at highs of $0.0899 a share, it is yet to break its tight trading range between $0.08 and $0.09 a share with its 52-week high currently standing at highs of $0.60 a share. Thus, there is tremendous upside potential for the stock to make movement and looks like the recent news is going to get the rally started.
Regen BioPharma Novel Treatment
The stocks sentiments on the street are highly dependent on the outcome of its ongoing clinical trials as well as studies of it small molecule N22F6 Modulators. The biopharmaceutical company is currently working on a second-generation immuno-oncology drug that has already shown the ability to bolster the body’s ability to fight cancer. The candidate drug has already proved to be effective in silencing, Indoleamine 2,3-dioxygenase (IDO) an enzyme known to suppress immune system’s ability to shrug off various types of cancers. The company has since provided the agency additional data and clarifications as requested awaiting verdict.
Even as Regen BioPharma awaits the FDA verdict on its new novel treatment for fighting cancer, it is business as usual for Amgen, which has achieved a new milestone with its migraine treatment. The giant drug maker has confirmed that its candidate drug succeeded in a late-stage trial having successfully reduced the number of migraine days in patients with an episodic migraine. Amgen, Inc. (NASDAQ:AMGN) is co-developing the migraine drug with Novartis AG (ADR) (NYSE:NVS) which if approved will compete for market share against Erenumab which is also being tested for chronic migraine prevention.
Merck Q3 Earnings
Separately Merck & Co., Inc. (NYSE:MRK) posted impressive third quarter earnings attributed to the acquisitions of the Sigma-Aldrich. Sales in the quarter were up by 19.1% to highs of $4.1 billion, with organic sales driven by the Life sciences segment increasing by 0.9%. The company has since reiterated its full year guidance where it expects net sales to come in the range of €14.9–€ 15.1 billion.
